– CANADA, Edmonton – Nanostics Inc., a precision health diagnostics company, today announced the appointment of Aubrey Rankin to its Board as an Independent Director, replacing Reg Joseph.
“We’re excited to announce Aubrey Rankin’s appointment to Nanostics’ Board of Directors. Aubrey’s vast experience and insights with patient-provider subscription platforms will be invaluable as we launch our lead prostate cancer diagnostic test, ClarityDX Prostate,” said CEO, John Lewis.
About Aubrey Rankin
Mr. Rankin’s extensive experience spans divergent industries including MedTech, FinTech, Software, and Professional Services, and has held various leadership roles including founder, CEO, board member, and investor. Most recently, Mr. Rankin served as President of Innovation (Software) and Member of the Board of Directors at Revance (Nasdaq: RVNC) where he oversaw the integration of HintMD, a FinTech company he co-founded in 2014. Revance (Nasdaq: RVNC) acquired HintMD’s Patient-Provider Subscription platform that supports personalized patient treatment plans in 2020.
His other experience includes serving as VP of Asia-Pacific at ZELTIQ (formerly Nasdaq: ZLTQ), bringing innovative marketing strategies and physician training academies to the medical aesthetics industry. He was also a director with PwC’s Mergers and Acquisitions Advisory group, assisting multinational clients with billion-dollar M&A, divestitures, and strategic alliance projects. Currently, Mr. Rankin serves on the board of directors of FriendMedia, and the advisory boards of two early-stage companies, RapidFort and PB&B.
Nanostics is thankful to outgoing board member Reg Joseph, CEO of Health City, for his service. Reg’s insights into the Healthcare Industry were instrumental in helping Nanostics advance its lead diagnostic product, ClarityDX Prostate through clinical studies and position it for regulatory approval.
Nanostics’ ClarityDX Prostate test uses a proprietary neural network algorithm that combines data from biological and clinical biomarkers to generate a risk score for clinically significant prostate cancer. The ClarityDX Prostate test is intended to be used by men with elevated levels of PSA. It is designed to help physicians and patients make a more informed decision on whether to proceed with a biopsy or not.
About Nanostics Inc.
Nanostics is a private Canadian company focused on developing and commercializing novel and noninvasive diagnostic tests. Its core technology, ClarityDX, uses advanced machine learning algorithms to create a disease risk score. ClarityDX applies to a wide range of cancers and other diseases. Nanostics’ lead product, ClarityDX Prostate, is a test that improves the accuracy of detecting clinically significant prostate cancer.
For more information: https://www.nanosticsdx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.